Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What’s Next? Five Things To Look Out For In September

Key Vascepa Appeal Kicks Off

Executive Summary

In September, Dr Reddy’s and Hikma will brace themselves for the beginning of Amarin’s appeal over its Vascepa (icosapent ethyl) patent-litigation defeat, while the final financial results for the 30 June quarter and year-end will trickle in.

You may also be interested in...



Gedeon Richter Gearing Up For Denosumab And Tocilizumab

Hungary’s Gedeon Richter is continuing efforts to bring multiple biosimilars to market, while reaping the benefits of the biosimilar to Eli Lilly’s Forsteo (teriparatide) in the EU and Japan. Management discussed Richter’s achievements on the company’s first-half earnings call, while also commenting on how markets have reacted to the COVID-19 pandemic.

Amarin Makes Vascepa Generics Prediction And Questions Supply

Amarin – and the industry at large – was stunned in March this year when Hikma and Dr Reddy’s walked away from court with an invalidity ruling against six Vascepa patents in the US. The originator’s CEO gave an impassioned update on the current state of play, including the potential for generics to launch ahead of a Federal Circuit ruling later this year or early in 2021.

Teva Moves On From Restructuring To Improving Margins

Teva has expanded on plans to improve its profit margins after emerging from a years-long restructuring program that has cut its cost base by over $3bn. The Israeli company reported first-quarter sales ahead by 5% to $4.36bn, seeing a “mixed bag” effect from the COVID-19 pandemic as well as positive results from new launches including two US biosimilars.

Related Content

Topics

UsernamePublicRestriction

Register

GB150212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel